CYP19A1 and breast cancer: Although aromatase inhibitors are currently available for breast cancer treatment in postmenopausal women, tamoxifen is still the “gold standard” of breast cancer therapy because it is cost effective, life saving and is devoid of major adverse side effects in the majority of patients [5], [6].